Related Experiment Video
Updated: Mar 12, 2026
Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer
Brian Y Park1, Rachel N Grisham2, Bjørnar den Hollander3
1a Department of Internal Medicine , Loma Linda University Medical Center , Loma Linda , California , USA.
Objectives:
To investigate the tumor-suppressive properties of enzalutamide in androgen-driven ovarian cancer.
Methods:
Mice were implanted subcutaneously with OVCAR-3 cells and treated with dihydrotestosterone in combination with enzalutamide or vehicle control. Tumor volumes were measured twice weekly until day 56.
Results:
Dihydrotestosterone exposure led to a significant increase in tumor growth, while concomitant treatment with enzalutamide led to significant reductions in tumor volume compared to the androgen-exposed groups.
Conclusions:
We present the first evidence that the second-generation anti-androgen enzalutamide may possess efficacy in the treatment of ovarian cancer, paving the way for the future clinical trials.
Insights
Enzalutamide, an anti-androgen, demonstrated tumor-suppressive effects in a mouse model of ovarian cancer. This finding suggests potential new therapeutic strategies for ovarian cancer treatment.
Area of Science:
- Oncology
- Endocrinology
Background:
- Ovarian cancer is a significant cause of cancer-related mortality.
- Androgen receptor signaling plays a role in certain ovarian cancer subtypes.
Purpose of the Study:
- To evaluate the efficacy of enzalutamide, a second-generation anti-androgen, as a potential treatment for ovarian cancer.
- To investigate the tumor-suppressive properties of enzalutamide in an androgen-driven ovarian cancer model.
Main Methods:
- OVCAR-3 ovarian cancer cells were xenografted into mice.
- Mice were treated with dihydrotestosterone to stimulate tumor growth.
- Tumor volumes were measured following treatment with enzalutamide or vehicle control.
Main Results:
- Dihydrotestosterone administration significantly increased ovarian cancer tumor volume.
- Concomitant treatment with enzalutamide significantly reduced tumor volume compared to androgen-exposed controls.
- Enzalutamide demonstrated notable tumor-suppressive activity in this preclinical model.
Conclusions:
- This study provides the first evidence for the potential efficacy of enzalutamide in ovarian cancer treatment.
- Enzalutamide's anti-androgenic properties may offer a novel therapeutic avenue for ovarian cancer.
- These findings support the progression of enzalutamide into future clinical trials for ovarian cancer.
More Related Videos
08:13Using the Chicken Chorioallantoic Membrane In Vivo Model to Study Gynecological and Urological Cancers
Published on: January 28, 2020
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018